Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
Planning a stem cell treatment abroad involves more than choosing a clinic. Adipose-derived stem cell therapy in Japan is a multi-step process, and the steps do not all happen on the same day. For international patients, that means thinking about timing, communication and follow-up before booking flights. This article outlines practical questions to consider when exploring adipose-derived stem cell therapy at Grand Green Osaka Umekita Clinic in Osaka, so that you arrive at your consultation well prepared.
In short: the treatment is not a single-visit procedure, it is provided as a self-pay service, and whether it is appropriate for you can only be decided by a physician after an in-person or remote consultation. The sections below explain why scheduling and communication deserve as much attention as the treatment itself.
Why this treatment needs more planning than a typical clinic visit
Adipose-derived stem cell therapy uses mesenchymal stem cells taken from a small amount of your own fat tissue. The cells are cultured and expanded at a specialized facility and later returned to the body by intravenous infusion. Because the cells are grown between collection and infusion, there is a waiting period that you cannot shorten by arriving earlier or staying longer.
This structure is different from many treatments that international patients are used to. A single trip is rarely enough to understand the whole process. Instead, patients usually need to think about at least two separate points of contact with the clinic: the stage where fat tissue is collected, and the later stage where the cultured cells are administered. Ask the clinic how these stages are expected to be arranged in your situation, and whether any part can be coordinated remotely.
Questions to ask about scheduling and travel
Before you book travel, it helps to write down the questions that affect your calendar. Timelines vary between individuals and depend on medical judgment, so treat any figure you read online as a general reference rather than a promise. The clinic’s physicians and coordinators are the right people to confirm what applies to you.
- How many visits to Osaka are expected, and what happens at each one?
- How long is the interval between fat collection and infusion, and could it change?
- What should I do if my travel dates change or my health status changes before a visit?
- Is there any activity, medication or supplement I should discuss with the physician before collection day?
- Can parts of the consultation or follow-up be done online?
Avoid booking non-refundable travel until you have received a clear explanation from a physician. Because the treatment depends on an individual assessment, it is possible that a doctor will advise waiting, undergoing further tests, or choosing a different approach.
How language and records support safe decisions
Clear communication is a safety issue, not just a convenience. You will need to discuss your medical history, current medications, allergies and the conditions you hope to address. Misunderstandings at this stage can affect the quality of the physician’s judgment.
Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka and provides an information page for international patients in multiple languages. Reading it before your consultation can help you learn the basic terminology and the general flow of care. It is still a good idea to ask how interpretation will work during the consultation itself, and whether written explanations and consent documents are available in a language you can read comfortably.
It is also worth gathering your existing medical records before you travel. Useful items may include recent test results, imaging reports, a list of current medications, and a summary from your regular physician. Ask the clinic in advance which documents are helpful and in what format they should be sent.
Understanding the Japanese regulatory framework
In Japan, regenerative medicine that involves cultured cells is regulated under the Act on the Safety of Regenerative Medicine. Clinics that offer this type of care submit a treatment plan to the authorities, and the cell processing is carried out under defined standards. This framework is intended to support safety management, but it does not mean that a specific outcome is guaranteed, and it does not replace your own careful review.
This treatment is provided as a self-pay service and is generally not covered by public health insurance. That is why you should ask for a written explanation of costs, what is included, and what is not included, before you decide. Because international patients may also need to consider travel, accommodation and possible additional visits, a complete picture of the overall budget is important. Do not rely on estimates from third-party websites; confirm everything with the clinic.
Risks, limits of evidence and follow-up after you return home
Every medical procedure carries risks. For this therapy, the steps include a minor procedure to collect fat tissue under local anesthesia, followed by an intravenous infusion. Possible concerns can include discomfort or bruising at the collection site, reactions related to the infusion, and individual responses that cannot be predicted in advance. Ask your physician to explain the risks and side effects that apply to you in plain language.
It is equally important to understand the state of the evidence. Research on mesenchymal stem cells is active worldwide, and some findings are promising, but results from laboratory studies or small clinical studies cannot be assumed to apply to every patient. Stem cell therapy should not be seen as a replacement for standard medical care. If you are receiving treatment for a condition at home, keep your regular doctor informed and do not stop any prescribed therapy without medical advice.
Finally, plan for the period after treatment. Ask how you can contact the clinic if you have questions after returning home, what symptoms should prompt you to seek medical attention locally, and how information can be shared with your doctor in your home country. A clear follow-up plan is part of responsible care.
Practical next steps before you decide
If you are considering adipose-derived stem cell therapy in Osaka, a calm, step-by-step approach tends to work best. Begin by reading the clinic’s treatment page, then prepare your questions and medical records, and request a consultation. Treat the consultation as a chance to ask whether the therapy suits your circumstances, not as a commitment.
- Review the treatment information, including the flow, fees and FAQ pages.
- Organize your medical history, medication list and test results.
- Write down your questions about schedule, cost, risks and follow-up.
- Ask for a physician’s assessment before arranging flights or accommodation.
- Keep your regular doctor informed about your plans.
Adipose-derived stem cell therapy is a self-pay regenerative treatment provided under Japanese regulation, and its suitability, costs, risks and side effects can only be confirmed by a physician after examination. Grand Green Osaka Umekita Clinic welcomes inquiries from international patients who want to understand the process before making any decisions.
- 1Gather recordsHistory, medications, test results
- 2Prepare questionsSchedule, cost, risks, follow-up
- 3Physician assessmentBefore booking travel
- 4Plan the visitsCollection and infusion stages
- 5Follow-upStay in touch after returning home
This diagram is a conceptual summary of the article content
References
- PubMed: Topical and intravenous administration of human umbilical cord mesenchymal stem cells in patients with diabetic foot ulcer and peripheral arterial disease: a phase I pilot study with a 3-year follow-up. (2022)
- PubMed: Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). (2017)
- PubMed: Adipose-derived mesenchymal stem cells for the treatment of Amyotrophic Lateral Sclerosis. A phase I/II safety and efficacy clinical trial. (2025)
- PubMed: Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: a randomized controlled trial. (2023)
- PubMed: Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae. (2025)
- PMC: Optimal Intravenous Administration Procedure for Efficient Delivery of Canine Adipose-Derived Mesenchymal Stem Cells. (2022)
- PMC: Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson's Disease: A Randomized, Double-Blind Clinical Trial. (2026)
- PMC: A prospective single-arm study on the effects of repeated intravenous infusions of canine adipose-derived mesenchymal stromal cells in dogs with chronic inflammatory enteropathy. (2025)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.